5HLB | pdb_00005hlb

E. coli PBP1b in complex with acyl-aztreonam and moenomycin


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.42 Å
  • R-Value Free: 
    0.243 (Depositor), 0.256 (DCC) 
  • R-Value Work: 
    0.225 (Depositor), 0.238 (DCC) 
  • R-Value Observed: 
    0.226 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 5HLB

Ligand Structure Quality Assessment 


This is version 1.4 of the entry. See complete history

Literature

Escherichia coli Penicillin-Binding Protein 1B: Structural Insights into Inhibition.

King, D.T.Wasney, G.A.Nosella, M.Fong, A.Strynadka, N.C.

(2016) J Biological Chem 

  • DOI: https://doi.org/10.1074/jbc.M116.718403
  • Primary Citation Related Structures: 
    5HL9, 5HLA, 5HLB, 5HLD

  • PubMed Abstract: 

    In Escherichia coli, the peptidoglycan cell wall is synthesized by bifunctional penicillin-binding proteins such as PBP1b that have both transpeptidase and transglycosylase activities. The PBP1b transpeptidase domain is a major target of β-lactams, and therefore it is important to attain a detailed understanding of its inhibition. The peptidoglycan glycosyltransferase domain of PBP1b is also considered an excellent antibiotic target yet is not exploited by any clinically approved antibacterials. Herein, we adapt a pyrophosphate sensor assay to monitor PBP1b-catalyzed glycosyltransfer and present an improved crystallographic model for inhibition of the PBP1b glycosyltransferase domain by the potent substrate analog moenomycin. We elucidate the structure of a previously disordered region in the glycosyltransferase active site and discuss its implications with regards to peptidoglycan polymerization. Furthermore, we solve the crystal structures of E. coli PBP1b bound to multiple different β-lactams in the transpeptidase active site and complement these data with gel-based competition assays to provide a detailed structural understanding of its inhibition. Taken together, these biochemical and structural data allow us to propose new insights into inhibition of both enzymatic domains in PBP1b.


  • Organizational Affiliation
    • From the Department of Biochemistry and Molecular Biology and Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, V6T 1Z3, Canada.

Macromolecule Content 

  • Total Structure Weight: 85.3 kDa 
  • Atom Count: 6,076 
  • Modeled Residue Count: 733 
  • Deposited Residue Count: 747 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Penicillin-binding protein 1B747Escherichia coli K-12Mutation(s): 0 
Gene Names: mrcBpbpFponBb0149JW0145
EC: 2.4.1.129 (PDB Primary Data), 3.4 (PDB Primary Data), 2.4.99.28 (UniProt), 3.4.16.4 (UniProt)
Membrane Entity: Yes 
UniProt
Find proteins for P02919 (Escherichia coli (strain K12))
Explore P02919 
Go to UniProtKB:  P02919
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP02919
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 2 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
M0E

Query on M0E



Download:Ideal Coordinates CCD File
B [auth A]MOENOMYCIN
C69 H106 N5 O34 P
NXPRJQIAIORCGO-ZLPAOQQDSA-N
AZR

Query on AZR



Download:Ideal Coordinates CCD File
C [auth A]2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl)-2-oxo-2-{[(2S,3S)-1-oxo-3-(sulfoamino)butan-2-yl]amino}ethylidene]amino}oxy)-2-methylpropanoic acid
C13 H19 N5 O8 S2
OEVQTUTXOVDNJO-GEEOIBTQSA-N

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.42 Å
  • R-Value Free:  0.243 (Depositor), 0.256 (DCC) 
  • R-Value Work:  0.225 (Depositor), 0.238 (DCC) 
  • R-Value Observed: 0.226 (Depositor) 
Space Group: P 2 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 62.53α = 90
b = 64.39β = 90
c = 301.4γ = 90
Software Package:
Software NamePurpose
BUSTERrefinement
xia2data reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Canadian Institutes of Health Research (CIHR)Canada--
Howard Hughes Medical Institute (HHMI)United States--
Canadian Foundation for InnovationCanada--
British Columbia Knowledge Development FundCanada--
Canada Research Chair ProgramsCanada--

Revision History  (Full details and data files)

  • Version 1.0: 2016-12-14
    Type: Initial release
  • Version 1.1: 2017-09-20
    Changes: Author supporting evidence
  • Version 1.2: 2019-11-20
    Changes: Author supporting evidence
  • Version 1.3: 2023-09-27
    Changes: Data collection, Database references, Refinement description
  • Version 1.4: 2024-11-06
    Changes: Structure summary